Home/Indications/Immunology/Crohn's Disease

Crohn's Disease

Immunology 5 original drugs

Novel Drugs

Reformulations

Drug Targets

Immunology indication. Crohn's Disease has 5 FDA-approved novel treatments, led by Eli Lilly, with 142 active industry clinical trials across 8 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Crohn's Disease Market Leaders

Companies with the most FDA-approved novel Crohn's Disease drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

—

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Estimated · stale NCT06925594

Q1 2027

Guselkumab

Johnson & Johnson

Estimated · fresh NCT05347095

Q1 2027

Risankizumab SC

AbbVie

Estimated · aging NCT06063967

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Crohn's Disease Treatments by Mechanism

Top 10 mechanisms across 55 industry trials with a known mechanism of action.

See full pipeline →

Interleukin-23 Antagonist

9 trials 6 active 2 sponsors

Integrin Receptor Antagonist

16 trials 3 active 3 sponsors

Janus Kinase Inhibitor

4 trials 2 active 1 sponsor

Tumor Necrosis Factor Blocker

8 trials 1 active 7 sponsors

Interleukin-12 Antagonist

5 trials 1 active 1 sponsor

TNF

8 trials 2 sponsors

Interleukin-17 Receptor A Antagonist

2 trials 1 sponsor

Central Nervous System Stimulant

1 trials 1 sponsor

Corticosteroid

1 trials 1 sponsor

Tyrosine Kinase 2 Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Crohn's Disease Clinical Pipeline by Phase

300 industry-sponsored trials across 102 sponsors

View full landscape →

Showing 21 of 21 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Taizhou Mabtech Pharmaceutical Co.,Ltd	Infliximab	Tumor Necrosis Factor Blocker [EPC]	RECRUITING	2026-11	NCT05906576
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	RECRUITING	2027-06-28	NCT06045754
Xian-Janssen Pharmaceutical Ltd.	Guselkumab (GUS)	—	RECRUITING	2027-09-15	NCT07310095
Takeda	Vedolizumab IV	—	RECRUITING	2027-10-01	NCT06581328
Takeda	—	—	ACTIVE NOT RECRUITING	2026-07-20	NCT04809363
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	NOT YET RECRUITING	2027-08-31	NCT07654751
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TyboWe® Adalimumab Injection	—	NOT YET RECRUITING	2028-12	NCT07663526
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Adalimumab Solution for Injection	—	NOT YET RECRUITING	2029-03	NCT07564505
Rubix LS	Mirikizumab	—	NOT YET RECRUITING	2026-01-01	NCT07059130
Johnson & Johnson	Ustekinumab	Interleukin-12 Antagonist [EPC]	COMPLETED	2025-05-18	NCT05029921
Takeda	Vedolizumab IV	—	COMPLETED	2024-02-02	NCT04804540
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2020-09-22	NCT02764762
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2019-02-22	NCT02559713
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2018-09-04	NCT02630966
AbbVie	adalimumab	TNF	COMPLETED	2016-08	NCT02148718
Janssen Inc.	Infliximab 5 mg/kg body weight infused over 2 hours	—	COMPLETED	2013-01	NCT01181765
Takeda	Darvadstrocel	—	TERMINATED	2025-02-14	NCT04118088
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	TERMINATED	2023-01-03	NCT02743806
Merck	Infliximab 5 mg/kg	—	TERMINATED	2010-06	NCT00752622
Takeda	Caffeine	Central Nervous System Stimulant [EPC]	WITHDRAWN	2020-08-01	NCT02760615
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	WITHDRAWN	2010-05	NCT00801125

Showing 100 of 117 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	—	—	RECRUITING	2026-12-28	NCT06925594
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	RECRUITING	2027-06	NCT06332534
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	RECRUITING	2027-06-08	NCT06227910
Takeda	Vedolizumab IV	—	RECRUITING	2027-09-13	NCT04779320
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	RECRUITING	2027-10-27	NCT05923073
Takeda	Vedolizumab IV	—	RECRUITING	2027-11-15	NCT06100289
Eli Lilly	Mirikizumab	—	RECRUITING	2027-12	NCT05509777
Eli Lilly	Mirikizumab	—	RECRUITING	2028-05	NCT06937099
Johnson & Johnson	JNJ-78934804	—	RECRUITING	2028-06-12	NCT07577843
Johnson & Johnson	Icotrokinra	—	RECRUITING	2028-09-19	NCT07196722
Merck	IV Tulisokibart	—	RECRUITING	2028-10-30	NCT06430801
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	RECRUITING	2028-11-15	NCT07499232
Roche	Afimkibart	—	RECRUITING	2028-12-31	NCT06819891
Roche	Afimkibart	—	RECRUITING	2028-12-31	NCT06819878
AbbVie	Risankizumab	—	RECRUITING	2029-04	NCT05995353
Sanofi	Duvakitug	—	RECRUITING	2029-05-14	NCT07184931
Sanofi	Duvakitug	—	RECRUITING	2029-08-13	NCT07184944
Takeda	Vedolizumab IV	—	RECRUITING	2030-03-08	NCT05837897
Roche	Afimkibart	—	RECRUITING	2030-05-31	NCT07298421
Takeda	Vedolizumab SC	—	RECRUITING	2030-08-12	NCT06405087
Eli Lilly	Mirikizumab	—	RECRUITING	2030-12	NCT04844606
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	RECRUITING	2031-12-12	NCT06663332
Takeda	Vedolizumab IV	—	RECRUITING	2033-02-07	NCT05442567
Merck	Tulisokibart	—	RECRUITING	2037-12-17	NCT06651281
AbbVie	Risankizumab SC	—	ACTIVE NOT RECRUITING	2027-03	NCT06063967
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-03-25	NCT05347095
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-06-08	NCT06408935
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-09	NCT03345823
Johnson & Johnson	Ustekinumab	Interleukin-12 Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-09-29	NCT05092269
AbbVie	Risankizumab	—	ACTIVE NOT RECRUITING	2028-02	NCT04524611
AbbVie	Risankizumab IV	—	ACTIVE NOT RECRUITING	2026-05	NCT03105102
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2025-05-30	NCT04738942
Eli Lilly	Mirikizumab	—	ACTIVE NOT RECRUITING	2024-11-28	NCT04232553
Johnson & Johnson	Guselkumab Dose 1	—	ACTIVE NOT RECRUITING	2023-10-20	NCT03466411
Johnson & Johnson	Guselkumab Dose 1	—	ACTIVE NOT RECRUITING	2023-07-04	NCT05197049
Johnson & Johnson	Ustekinumab	Interleukin-12 Antagonist [EPC]	COMPLETED	2024-11-28	NCT04673357
Takeda	Vedolizumab SC	—	COMPLETED	2024-06-12	NCT02620046
Takeda	Darvadstrocel	—	COMPLETED	2024-04-02	NCT04075825
Janssen Pharmaceutical K.K.	Guselkumab	Interleukin-23 Antagonist [EPC]	COMPLETED	2024-02-29	NCT04397263
Takeda	25 mg Ontamalimab	—	COMPLETED	2023-12-13	NCT03283085
Bristol-Myers Squibb	Ozanimod	—	COMPLETED	2023-11-21	NCT03440385
Eli Lilly	Mirikizumab	—	COMPLETED	2023-08-23	NCT03926130
Tigenix S.A.U.	Cx601	—	COMPLETED	2023-01-23	NCT03279081
Galapagos NV	Filgotinib	—	COMPLETED	2022-11-11	NCT02914561
Celltrion	CT-P13 SC (Infliximab)	—	COMPLETED	2022-08-23	NCT03945019
Johnson & Johnson	Ustekinumab approximately 6 mg/kg (IV)	—	COMPLETED	2022-08-19	NCT03782376
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-10-15	NCT03345849
Roche	Etrolizumab	—	COMPLETED	2021-09-07	NCT02394028
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-08-11	NCT03345836
Janssen Scientific Affairs, LLC	Ustekinumab (6 mg/kg)	—	COMPLETED	2020-12-15	NCT03464136
AbbVie	risankizumab SC	—	COMPLETED	2020-11-30	NCT03104413
AbbVie	risankizumab IV	—	COMPLETED	2020-11-09	NCT03105128
Takeda	Vedolizumab IV	—	COMPLETED	2020-08-14	NCT03234907
Takeda	Darvadstrocel	—	COMPLETED	2020-07-20	NCT03706456
Johnson & Johnson	Ustekinumab	Interleukin-12 Antagonist [EPC]	COMPLETED	2020-04-30	NCT03107793
AbbVie	Adalimumab	TNF	COMPLETED	2020-01-30	NCT02065570
Takeda	Vedolizumab SC 108 mg	—	COMPLETED	2019-05-06	NCT02611817
Boehringer Ingelheim	BI 695501	—	COMPLETED	2019-04-30	NCT02871635
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2019-01-25	NCT02038920
RedHill Biopharma Limited	RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)	—	COMPLETED	2018-11-13	NCT03009396
Shield Therapeutics	Ferric Maltol	—	COMPLETED	2018-10	NCT02680756
UCB Biopharma S.P.R.L.	e-Device	—	COMPLETED	2018-07-02	NCT03357471
RedHill Biopharma Limited	RHB-104	—	COMPLETED	2018-05	NCT01951326
AbbVie	Adalimumab	TNF	COMPLETED	2017-11-03	NCT02185014
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2017-10-31	NCT00790933
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2017-06-02	NCT02425111
AbbVie	adalimumab	TNF	COMPLETED	2017-05-19	NCT02499783
AbbVie (prior sponsor, Abbott)	Adalimumab	TNF	COMPLETED	2017-04-04	NCT00686374
AbbVie (prior sponsor, Abbott)	Adalimumab	TNF	COMPLETED	2016-11-03	NCT01235689
Celltrion	CT-P13	—	COMPLETED	2016-01-11	NCT02096861
Tigenix S.A.U.	—	—	COMPLETED	2015-07	NCT01541579
Johnson & Johnson	Ustekinumab 90 mg SC q8w	—	COMPLETED	2015-06-10	NCT01369355
Tanabe Pharma Corporation	TA-650	—	COMPLETED	2015-03	NCT01580670
AbbVie	Adalimumab	TNF	COMPLETED	2015-03	NCT01958827
UCB BIOSCIENCES GmbH	Cimzia	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2014-12	NCT00552344
Mesoblast, Inc.	Prochymal®	—	COMPLETED	2014-09-15	NCT01233960
Padagis LLC	Entocort	—	COMPLETED	2014-09	NCT01444092
AstraZeneca	D9421-C capsule 3 mg	—	COMPLETED	2014-09	NCT01514240
Johnson & Johnson	Group 2 ustekinumab 130 mg	—	COMPLETED	2014-08	NCT01369342
Padagis LLC	Entocort	—	COMPLETED	2014-02	NCT01453946
Shield Therapeutics	ST10	—	COMPLETED	2013-10	NCT01352221
GSK	GSK1605786A	—	COMPLETED	2013-07-11	NCT01277666
Johnson & Johnson	Group 2 ustekinumab 130 mg	—	COMPLETED	2013-06	NCT01369329
Otsuka Pharmaceutical Co., Ltd.	OPC-6535	—	COMPLETED	2012-08	NCT00989573
Millennium Pharmaceuticals, Inc.	vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2012-03	NCT00783692
Millennium Pharmaceuticals, Inc.	vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2012-02	NCT01224171
Vifor Pharma	Ferric carboxymaltose	—	COMPLETED	2009-12	NCT00810030
Tanabe Pharma Corporation	TA-650	—	COMPLETED	2009-11	NCT00805766
UCB Pharma	certolizumab pegol (CDP870, CZP)	—	COMPLETED	2009-10	NCT00552058
Takeda	Darvadstrocel	—	TERMINATED	2025-05-07	NCT04701411
Pfizer	Etrasimod	—	TERMINATED	2025-04-23	NCT04173273
Bristol-Myers Squibb	Ozanimod	—	TERMINATED	2024-10-31	NCT03467958
Bristol-Myers Squibb	Ozanimod	—	TERMINATED	2024-10-03	NCT03464097
Bristol-Myers Squibb	Ozanimod	—	TERMINATED	2024-10-01	NCT03440372
Bristol-Myers Squibb	Ozanimod	—	TERMINATED	2024-09-13	NCT05470985
AstraZeneca	Brazikumab low dose	—	TERMINATED	2023-10-18	NCT03759288
Roche	Etrolizumab	—	TERMINATED	2023-10-09	NCT02403323
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	TERMINATED	2023-09-29	NCT05784129
AstraZeneca	Brazikumab Induction Dose	—	TERMINATED	2023-09-19	NCT03961815
Galapagos NV	Filgotinib	—	TERMINATED	2023-08-01	NCT02914600

Showing 100 of 117 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Takeda	TAK-279	—	RECRUITING	2026-09-18	NCT06233461
Abivax S.A.	Obefazimod	—	RECRUITING	2026-12	NCT06456593
Sanofi	SAR442970	—	RECRUITING	2026-12-17	NCT06958536
Mirador Therapeutics, Inc.	MT-501	—	RECRUITING	2027-04-30	NCT07113522
Biocad	anti-TL1A monoclonal antibody, low dose	—	RECRUITING	2027-05	NCT07078994
Eli Lilly	LY4395089	—	RECRUITING	2027-06	NCT07483099
Eli Lilly	Mirikizumab - Intravenous (IV)	—	RECRUITING	2027-06	NCT07483073
Sanofi	SAR441566	—	RECRUITING	2027-07-21	NCT06637631
Direct Biologics, LLC	DB-3Q	—	RECRUITING	2027-07-30	NCT06918808
Hope Biosciences Research Foundation	HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells	—	RECRUITING	2027-12	NCT07077746
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)	MORF-057	—	RECRUITING	2028-09	NCT06226883
Takeda	Zasocitinib	—	RECRUITING	2029-12-30	NCT06764615
AbbVie	Risankizumab	—	RECRUITING	2030-01	NCT06548542
Tr1X, Inc.	TRX103	—	RECRUITING	2026-01-30	NCT06721962
AstraZeneca	AZD7798	—	ACTIVE NOT RECRUITING	2026-08-20	NCT06681324
Agomab Spain S.L.U.	AGMB-129	—	ACTIVE NOT RECRUITING	2026-09	NCT05843578
Roche	Afimkibart	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05910528
Intralytix, Inc.	Bacteriophage preparation	—	ACTIVE NOT RECRUITING	2026-06-01	NCT03808103
AstraZeneca	AZD7798	—	ACTIVE NOT RECRUITING	2026-04-30	NCT06450197
Teva Branded Pharmaceutical Products R&D LLC	TEV-48574 Dose Regimen A	—	ACTIVE NOT RECRUITING	2026-01-05	NCT05668013
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	ACTIVE NOT RECRUITING	2025-05-23	NCT05242471
Avobis Bio, LLC	AVB-114	—	ACTIVE NOT RECRUITING	2025-05	NCT04847739
Direct Biologics, LLC	DB-3Q	—	NOT YET RECRUITING	2027-06	NCT07625293
Takeda	Zasocitinib	—	NOT YET RECRUITING	2028-03-30	NCT07403968
AbbVie	ABT-494	—	COMPLETED	2025-07-18	NCT02782663
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2025-04-03	NCT03196427
Teva Branded Pharmaceutical Products R&D, Inc.	TEV-48574	—	COMPLETED	2024-11-12	NCT05499130
Medibiofarma S.L.	MBF-118 oral capsules	—	COMPLETED	2024-09-10	NCT05940558
Pfizer	PF-06651600	—	COMPLETED	2023-10-19	NCT03395184
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	Human TH-SC01 cell injection	—	COMPLETED	2023-08-30	NCT05626023
Bristol-Myers Squibb	Deucravacitinib	Tyrosine Kinase 2 Inhibitor [EPC]	COMPLETED	2023-08-29	NCT04877990
Stero Biotechs Ltd.	Cannabidiol , synthetic form	—	COMPLETED	2022-11-07	NCT04056442
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Tulisokibart	—	COMPLETED	2022-09-23	NCT05013905
Lument AB	—	—	COMPLETED	2022-04-04	NCT04321941
EA Pharma Co., Ltd.	E6011	—	COMPLETED	2022-03-16	NCT03733314
Boehringer Ingelheim	Spesolimab	—	COMPLETED	2021-12-01	NCT03752970
Reistone Biopharma Company Limited	SHR0302	—	COMPLETED	2021-09-16	NCT03677648
Gilead	Filgotinib	—	COMPLETED	2021-01-20	NCT03077412
Johnson & Johnson	JNJ-64304500	—	COMPLETED	2020-12-10	NCT02877134
Gilead	Filgotinib	—	COMPLETED	2020-07-20	NCT03046056
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2020-03-31	NCT03138655
Bristol-Myers Squibb	RPC1063	—	COMPLETED	2019-09-12	NCT02531113
Provention Bio, Inc.	PRV-6527	—	COMPLETED	2019-08-13	NCT03854305
AbbVie	Risankizumab 600 mg IV	—	COMPLETED	2019-06-19	NCT02513459
VHsquared Ltd.	V565	—	COMPLETED	2019-03-08	NCT02976129
Eli Lilly	Mirikizumab	—	COMPLETED	2018-12-11	NCT02891226
Arena Pharmaceuticals	Olorinab	—	COMPLETED	2018-09-10	NCT03155945
UCB Pharma	certolizumab pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2017-11-27	NCT01190410
Tanabe Pharma Corporation	MT-1303	—	COMPLETED	2017-08	NCT02389790
EA Pharma Co., Ltd.	E6011 2 mg/kg	—	COMPLETED	2017-01-06	NCT02039063
AbbVie	ABT-494	—	COMPLETED	2016-11-25	NCT02365649
Tanabe Pharma Corporation	MT-1303	—	COMPLETED	2016-10	NCT02378688
Takeda	PF-00547659	—	COMPLETED	2016-07-27	NCT01298492
Pfizer	CP-690,550	—	COMPLETED	2016-07	NCT01470599
Pfizer	PF-04236921	—	COMPLETED	2016-03	NCT01345318
Qu Biologics Inc.	QBECO	—	COMPLETED	2016-02	NCT01809275
AbbVie	risankizumab IV	—	COMPLETED	2015-12	NCT02031276
Galapagos NV	GLPG0634	—	COMPLETED	2015-11	NCT02048618
Pfizer	CP-690,550	—	COMPLETED	2015-07	NCT01393899
AbbVie	Adalimumab	TNF	COMPLETED	2015-02	NCT02015793
Pfizer	CP-690,550	—	COMPLETED	2015-02	NCT01393626
Amgen	Abrilumab	—	COMPLETED	2014-12-26	NCT01696396
Novo Nordisk	NNC0114-0006	—	COMPLETED	2014-12	NCT01751152
Pfizer	PF-04236921 SC injection	—	COMPLETED	2014-09	NCT01287897
Medtronic - MITG	—	—	COMPLETED	2014-07	NCT01576120
Bristol-Myers Squibb	BMS-936557 (Anti-IP-10 Antibody)	—	COMPLETED	2014-06	NCT01466374
AstraZeneca	MEDI2070	—	COMPLETED	2014-05-20	NCT01714726
Takeda	PF-00547659 SC injection	—	COMPLETED	2014-02-07	NCT01276509
Medtronic - MITG	—	—	COMPLETED	2014-01	NCT01631435
Coronado Biosciences, Inc.	Trichuris suis ova (TSO)	—	COMPLETED	2013-10	NCT01576471
Johnson & Johnson	NNC 0142-0000-0002	—	COMPLETED	2013-05	NCT01203631
Novartis	QAX576	—	COMPLETED	2013-03	NCT01355614
Delenex Therapeutics AG	DLX105	—	COMPLETED	2013-02	NCT01624376
Neovacs	TNF Kinoid	—	COMPLETED	2012-10	NCT01291810
Celularity Incorporated	Human Placenta-Derived Cells PDA001 Intravenous Infusion	—	COMPLETED	2012-02	NCT01155362
Teva Branded Pharmaceutical Products R&D, Inc.	Laquinimod	—	COMPLETED	2011-11	NCT00737932
Neovacs	TNFa Kinoid	—	COMPLETED	2010-12	NCT00808262
Tigenix S.A.U.	Cx601	—	COMPLETED	2010-09	NCT01372969
Centocor, Inc.	Ustekinumab 1mg/kg (IP)	—	COMPLETED	2010-05	NCT00771667
Pfizer	CP-690,550	—	COMPLETED	2009-10	NCT00615199
Toray Industries, Inc	TRK-170	—	COMPLETED	—	NCT01345799
Direct Biologics, LLC	ExoFlo	—	TERMINATED	2024-12-01	NCT05836883
Boehringer Ingelheim	BI 706321	—	TERMINATED	2024-07-08	NCT04978493
Ventyx Biosciences, Inc	VTX958	—	TERMINATED	2024-06-27	NCT05688852
AbbVie	ABBV-154	—	TERMINATED	2023-07-20	NCT05068284
Bristol-Myers Squibb	BMS-986165	—	TERMINATED	2022-12-12	NCT03599622
NImmune Biopharma	BT-11 880 mg	—	TERMINATED	2022-08-26	NCT03870334
Takeda	TAK-018	—	TERMINATED	2022-08-25	NCT03943446
Roche	UTTR1147A	—	TERMINATED	2022-07-12	NCT03650413
Boehringer Ingelheim	Spesolimab	—	TERMINATED	2022-05-14	NCT04362254
Theravance Biopharma	TD-1473	—	TERMINATED	2021-12-30	NCT03635112
Johnson & Johnson	JNJ-67864238	—	TERMINATED	2021-11-17	NCT04102111
Qu Biologics Inc.	QBECO-SSI	—	TERMINATED	2020-12-20	NCT03472690
Alfasigma S.p.A.	Rifaximin delayed release tablets	—	TERMINATED	2020-07-15	NCT03537157
Otsuka Pharmaceutical Development & Commercialization, Inc.	OPS-2071	—	TERMINATED	2020-05-22	NCT03850509
Prometheus Laboratories	CROWN	—	TERMINATED	2018-06-01	NCT02793778
Bristol-Myers Squibb	GED-0301	—	TERMINATED	2017-09-25	NCT02685683
AstraZeneca	Brazikumab IV Infusion	—	TERMINATED	2017-07-28	NCT02574637
Gilead	Andecaliximab	—	TERMINATED	2016-11-30	NCT02405442
TxCell	Ovasave	—	TERMINATED	2016-11	NCT02327221

Showing 45 of 45 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
CryoCord Sdn Bhd	PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells	—	RECRUITING	2026-12-31	NCT05039411
Benethera (Shaoxing) Biotechnology Co., Ltd.	BDHK-2009 Tablets	—	RECRUITING	2026-12-31	NCT07632573
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	Mesenchymal Stem Cells (MSCs)	—	RECRUITING	2024-11	NCT06429241
Palisade Bio	PALI-2108	—	ACTIVE NOT RECRUITING	2026-01-30	NCT07428096
Lmito Therapeutics Inc.	LMT503	—	NOT YET RECRUITING	2025-10-01	NCT05659953
AstraZeneca	AZD7798	—	COMPLETED	2026-03-27	NCT06432764
Agomab Spain S.L.U.	AGMB-129	—	COMPLETED	2025-09-15	NCT07118878
Odyssey Therapeutics	OD-07656	—	COMPLETED	2024-11-25	NCT06206811
AstraZeneca	AZD7798	—	COMPLETED	2024-11-14	NCT05452304
AstraZeneca	AZD7798	—	COMPLETED	2024-10-08	NCT06053424
Athos Therapeutics Inc	ATH-063	—	COMPLETED	2024-02-08	NCT05807971
UCB Biopharma SRL	Pharmacokinetics of certolizumab pegol	—	COMPLETED	2023-05-23	NCT04163016
AbbVie	Risankizumab	—	COMPLETED	2022-10-14	NCT04254783
Fresenius Kabi SwissBioSim GmbH	40 mg MSB11022	—	COMPLETED	2020-03-17	NCT04018599
Roche	UTTR1147A	—	COMPLETED	2020-02-19	NCT02749630
Enterome	EB8018 (First-in-class FimH blocker)	—	COMPLETED	2019-11-12	NCT03709628
Celltrion	CT-P13	—	COMPLETED	2019-02-04	NCT02883452
Johnson & Johnson	Ustekinumab	Interleukin-12 Antagonist [EPC]	COMPLETED	2018-09-19	NCT02968108
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2018-07-26	NCT03329209
UCB BIOSCIENCES, Inc.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-10	NCT02019602
Bristol-Myers Squibb	GED-0301	—	COMPLETED	2016-09-06	NCT02367183
VHsquared Ltd.	V565	—	COMPLETED	2016-03	NCT03010787
UCB BIOSCIENCES, Inc.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-12	NCT02154425
AstraZeneca	AMG 139	—	COMPLETED	2015-02-18	NCT01258205
Celularity Incorporated	PDA001	—	COMPLETED	2014-11	NCT01769755
Tanabe Pharma Corporation	MT-1303	—	COMPLETED	2014-06	NCT02148185
Amgen	AMG 181	—	COMPLETED	2014-04	NCT01290042
Takeda	lumbar puncture	—	COMPLETED	2014-03-31	NCT01387594
Novadaq Technologies ULC, now a part of Stryker	—	—	COMPLETED	2013-10	NCT01560377
GSK	GSK1605786 capsule	—	COMPLETED	2013-06-14	NCT01827631
Coronado Biosciences, Inc.	Trichuris suis ova	—	COMPLETED	2012-04	NCT01434693
GSK	GSK1605786 500 mg	—	COMPLETED	2011-11-10	NCT01489943
GSK	—	—	COMPLETED	2011-02	NCT01051622
GSK	GSK1605786	—	COMPLETED	2010-10-06	NCT01611805
GSK	GSK1605786 ChemoCentryx: formulation A	—	COMPLETED	2010-06-29	NCT01114607
Ferring Pharmaceuticals	CPSI-2364 or placebo	—	COMPLETED	2009-10	NCT00950105
Teva GTC	Delayed Release 6 mercaptopurine	—	COMPLETED	2009-02	NCT00774982
Direct Biologics, LLC	ExoFlo	—	TERMINATED	2024-12-01	NCT05130983
Exeliom Biosciences	EXL01	—	TERMINATED	2024-10-02	NCT05542355
Johnson & Johnson	Ustekinumab IV Infusion	—	TERMINATED	2021-11-22	NCT03358706
Avalo Therapeutics, Inc.	MDGN-002	—	TERMINATED	2021-09-14	NCT03169894
Roche	Etrolizumab	—	TERMINATED	2019-12-02	NCT03478956
Nutrition Science Partners Limited	HMPL004-6599	—	TERMINATED	2018-11-19	NCT03597971
Tiziana Life Sciences LTD	Foralumab	—	WITHDRAWN	2023-07-07	NCT05028946
Eisai Inc.	E6011	—	WITHDRAWN	2016-03	NCT02249078

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Crohn's Disease

TNF-alpha (20)

Novel Crohn's Disease Drugs by Company (New molecular entities)

5 companies have an FDA-approved novel drug for Crohn's Disease.

Eli Lilly 1 drug

OMVOH

MIRIKIZUMAB-MRKZ

BLA 2023

Johnson & Johnson 1 drug

Takeda 1 drug

Biogen 1 drug

UCB INC 1 drug

Reformulations (3 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Crohn's Disease Drug Targets

Molecular targets of approved and investigational Crohn's Disease drugs — 8 targets tracked.

TNF 15 IL-23 7 IL-12 6 Integrin alpha4beta7 3 Integrin alpha4beta1 2 TNFα 1 JAK1 1 JAK2 1

Biosimilars (21 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

Related Indications

Other Immunology indications

View all Immunology

Drug Categories:

Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
Biosimilars: BLA-approved biologics highly similar to reference products
Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology